Nuvalent NUVL 深 滬
已收盤 07-15 16:00:00 美东时间
123.96
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 123.96
- 總市值 98.09亿
- 52周最高 123.99
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 71.13
- 委 比 0.00%
- 總股本 7912.82万
- 歷史最高 123.99
- 量 比 0
- 振 幅 0.00%
- 歷史最低 7.09
- 每 手 1
- 風險率 8.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多葛兰素史克大举并购充实管线，明年在研抗癌药数量或将接近翻倍
葛兰素史克一位核心研发高管表示，公司预计明年处于临床试验阶段的抗癌候选药物数量几乎翻番，凸显一连串收购交易正在快速充实其新药管线。 这家英国药企肿瘤研发主管...
10-27 15:55
裁员2300人！GSK把省下的钱砸向了中国创新药
（来源：求实药社） 葛兰素史克（GSK）正经历一场冰火两重天的剧烈重塑。 一方面，其在欧洲挥舞裁员“大刀”，34天超2300个岗位被摆上砧板，以推进每年19亿...
10-22 12:00
GSK启动六部分美元债券发行，为Nuvalent收购案融资
葛兰素史克正在推销美元债券，以帮助为其106亿美元收购美国生物技术公司Nuvalent Inc.的过桥融资进行再融资。此前该制药商已完成了35亿欧元（约合41亿...
09-08 20:53
MNC百亿并购逻辑变了
原标题：MNC百亿并购逻辑变了 来源：动脉网 2026年全球医药领域百亿级并购热度重回高位： 6月艾伯维109亿美元拿下Apogee、GSK斥资106亿美元收...
08-21 09:09
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Fortress Biotech Q2 Earnings Preview
Fortress Biotech (FBIO) is scheduled to announce Q2 earnings results on Wednesday, August 12th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $18.3M (+...
08-12 05:35
GSK declares $0.4518/ADS or 17p/share dividend
GSK (GSK) declares approx. $0.4518 per ADS or 17.00p/share interim dividend, in line with previous, bringing total dividend declared to 70p/share for full year 2026. Payable Oct. 8; for shareholders o...
07-28 20:34
GSK announces $2.5B cost savings program to fund R&D
With its consensus-beating Q2 2026 results on Tuesday, GSK (GSK) announced a three-year program to reduce annual expenditure by £1.9B ($2.5B) in a bid to fund investment in its late-stage pipeline and...
07-28 20:01
GSK Non-GAAP EPS of £0.51 beats by £0.02, revenue of £8.41B beats by £4.05B; reaffirms FY2026 outlook
GSK press release (GSK): Q2 Non-GAAP EPS of £0.51 beats by £0.02. Revenue of £8.41B (+5.3% Y/Y) beats by £4.05B. Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £...
07-28 19:24
